Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.

Zofia Piotrowska,Daniel Shao-Weng Tan,Egbert F Smit,Alexander I Spira,Ross A Soo,Danny Nguyen,Victor Ho-Fun Lee,James Chih-Hsin Yang,Vamsidhar Velcheti,John M Wrangle,Mark A Socinski,Marianna Koczywas, John E Janik,Jeffrey Jones,Helena Alexandra Yu

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2023）

引用 1|浏览34

暂无评分

摘要

Zipalertinib has encouraging preliminary antitumor activity in heavily pretreated patients with ex20ins-mutant NSCLC, with an acceptable safety profile, including low frequency of high-grade diarrhea and rash.

查看译文

关键词

zipalertinib,epidermal growth factor receptor,lung cancer,antitumor activity,small-cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要